NEW YORK (GenomeWeb News) – Beckman Coulter has priced two senior notes offerings and has filed a prospectus to sell up to $250 million worth of common stock, which will help pay for its $780 million acquisition of Olympus' diagnostics business.

The offerings were expected, as Beckman said in late February that it would pay for the acquisition through a combination of around $500 million worth of new debt and roughly $300 million of its common stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.